Confident Investing Starts With TipRanks Premium

Oricell Therapeutics Holdings Limited

1227 Zhangheng Rd Third Floor, Building #1 Shanghai, CNhttps://www.oricell.com/en/Therapeutics

Oricell Therapeutics Holdings Limited is a clinical-stage biotechnology company developing next-generation cell therapies to address unmet needs in oncology and immunology, with a primary focus on CAR-T therapies for solid tumors. The company leverages three proprietary platforms—Ori®Ab for antibody discovery, Ori®Armoring to enhance T-cell persistence, and OnGo (Fast) CMC for rapid, scalable manufacturing—to advance a diversified pipeline of autologous, secreting, and in vivo CAR-T candidates.

Leadership & Board

Current Number of Employees: 25
Current LinkedIn Followers: 2,927

Latest Estimated Valuation

Estimated Valuation: ―
Total Amount Raised: $180M
Total Funding Rounds: 2
Latest Funding Amount: $110M
Latest Funding Round: Investment
Post-Money Valuation: ―

Employee Trend

Oricell Therapeutics Holdings Limited had 25 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.

25Latest Employee Count

0(0.00%)Week-Over-Week Change

Social Trend

Oricell Therapeutics Holdings Limited had 2,927 followers as of October 12, 2026. The number of followers increased by 3 (0.10%) week-over-week.

2,927Latest Followers Count

3(0.10%)Week-Over-Week Change

Funding Round

Funding Date	Funding Round	Amount Raised	Post-Money Valuation
Apr 10, 2026	Investment	$110.00M	―
Jan 13, 2026	Series C	$70.00M	―

Investors

Investor Name	Funding Round
Vivo Capital	Investment
Beijing Medical and Health Care Industry Investment Fund	Investment
Qiming Venture Partners	Investment
an international sovereign wealth fund	Investment
E-Town Capital	Investment
Luxin Venture Capital	Investment
NGS Super	Investment
Elikon Investment	Investment

Similar Companies

A snapshot of private companies similar to Oricell Therapeutics Holdings Limited, helping you discover and navigate related company profiles.

Zarminali Pediatrics

CARGO Therapeutics

Bridge to Life Ltd

Related News and Analysis

Oricell Wins NMPA Go-Ahead for Pivotal GPC3 CAR-T Trial in Advanced Liver Cancer

Oricell Wins NMPA Go-Ahead for Pivotal GPC3 CAR-T Trial in Advanced Liver Cancer

New updates have been reported about Oricell Therapeutics Holdings Limited. Oricell Therapeutics Holdings Limited has secured clearance from China’s National Medical Products Administration to launch a confirmatory Phase II, randomized,

4M ago

Oricell’s Lead CAR-T Asset Delivers 66.7% ORR in Late-Line Liver Cancer, Paving Path to Pivotal Phase II

Oricell’s Lead CAR-T Asset Delivers 66.7% ORR in Late-Line Liver Cancer, Paving Path to Pivotal Phase II

New updates have been reported about Oricell Therapeutics Holdings Limited. Oricell Therapeutics Holdings Limited reported that its lead GPC3-targeted CAR-T candidate, Ori-C101, produced a 66.7% objective response rate at the

5M ago

Oricell Raises Over $110 Million in Pre-IPO Round to Speed Global CAR-T Expansion

Oricell Raises Over $110 Million in Pre-IPO Round to Speed Global CAR-T Expansion

New updates have been reported about Oricell Therapeutics Holdings Limited. Oricell Therapeutics Holdings Limited has closed a pre-IPO financing round exceeding $110 million, providing substantial capital to accelerate its global

6M ago

Tamr Raises $21 Million to Scale AI-Native Master Data Management for Enterprise AI

Tamr Raises $21 Million to Scale AI-Native Master Data Management for Enterprise AI

New updates have been reported about Tamr. Tamr has secured $21 million in growth equity financing led by Volition Capital, with existing investors participating, to accelerate its AI-native master data

29m ago

Ande Deepens Corporate Entertainment Reach With SixPlus Licensing Deal

Ande Deepens Corporate Entertainment Reach With SixPlus Licensing Deal

New updates have been reported about Ande. Ande has signed a licensing agreement with private dining marketplace SixPlus, integrating SixPlus’s network of more than 600 restaurant, hotel, and activity partners

29m ago

ProphetX Taps Juice Reel Integration to Scale Regulated Sports Prediction Markets

ProphetX Taps Juice Reel Integration to Scale Regulated Sports Prediction Markets

New updates have been reported about ProphetX. ProphetX has entered a strategic integration with Juice Reel, embedding its CFTC‑regulated sports prediction exchange directly inside Juice Reel’s existing trade‑tracking and forecaster

30m ago

TIA Advances DCE 9000 Quality Standard as Data Center Investment Surges

TIA Advances DCE 9000 Quality Standard as Data Center Investment Surges

New updates have been reported about Tia. The Telecommunications Industry Association (TIA) has released the first draft of its DCE 9000 data center quality management standard, positioning the organization at

30m ago

ClassDojo Unveils New District Communication Tools Ahead of 2026–27 School Year

ClassDojo Unveils New District Communication Tools Ahead of 2026–27 School Year

New updates have been reported about ClassDojo. ClassDojo is expanding its district-focused communication platform with new capabilities designed for middle and high schools, underscoring its push to become a unified

30m ago

accessiBe Overhauls Partner Program to Capture Rising Web Accessibility Demand

accessiBe Overhauls Partner Program to Capture Rising Web Accessibility Demand

New updates have been reported about accessiBe. accessiBe has launched a significantly revamped Partner Program that positions the company at the center of growing global demand for web accessibility solutions,

30m ago

P2 Science Names Brian Freedman to Lead Marketing as Commercial Scale-Up Accelerates

P2 Science Names Brian Freedman to Lead Marketing as Commercial Scale-Up Accelerates

New updates have been reported about P2 Science. P2 Science, a privately held green chemistry company based in Woodbridge, Conn., has appointed Brian Freedman as Vice President of Marketing and

30m ago